Form 4: Caris Life Sciences Director Exercises Stock Options

Caris Life Sciences Director Peter M. Castleman exercised 2,500 stock options, acquiring common stock at $18.60 per share.

Summary

• Director Peter M. Castleman of Caris Life Sciences, Inc. (CAI) reported an insider transaction on January 9, 2026.
• Mr. Castleman exercised 2,500 stock options, acquiring common stock at an exercise price of $18.60 per share.
• Following this transaction, Mr. Castleman directly owns 18,629 shares of Caris Life Sciences common stock.
• He also indirectly holds 100,000 shares through a Family Trust and 10,270,906 shares through CLS-PF-SPE, LLC, where he has voting and investment power.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 6

Explanation: The transaction is a routine exercise of previously granted stock options by a director under a 10b5-1 plan. While it increases direct ownership, it is a pre-scheduled event and does not necessarily signal new information or strong conviction beyond the initial grant.

Positives

• Director Peter M. Castleman increased his direct beneficial ownership of Caris Life Sciences common stock by 2,500 shares.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary trade.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. Such filings are standard disclosures for public company directors and officers.

Related Party Transactions

• Peter M. Castleman indirectly holds 10,270,906 shares through CLS-PF-SPE, LLC, where he is a manager of CLS-PF-SPE Manager, LLC, and in such capacity has voting and investment power. He disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders may view the director's increased direct ownership as a minor positive signal of alignment with shareholder interests, although it is a routine, pre-scheduled transaction.

Key Dates

Recommendation

This Form 4 details a routine exercise of stock options by a director, Peter M. Castleman, under a pre-established Rule 10b5-1 trading plan. Such transactions are generally not considered strong indicators for a change in investment strategy as they are often pre-scheduled and do not reflect discretionary buying based on new material information. The increase in direct ownership is minor relative to the company's overall market capitalization and the director's total beneficial ownership. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a 'buy' or 'sell' decision.

Keywords

Caris Life Sciences, CAI, Form 4, Insider Transaction, Stock Option Exercise, Director, Beneficial Ownership, Rule 10b5-1